Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response

Science Translational Medicine

Volumn 5, Issue 175, 2013, Pages

  Colliou, Natacha ^a   Picard, Damien ^a   Caillot, Frédériqu ^a   Calbo, Sébastien ^a   Le Corre, Stéphanie ^b   Lim, Annick ^c   Lemercier, Brigitte ^c   Le Mauff, Brigitte ^d   Maho Vaillant, Maud ^a   Jacquot, Serge ^b   Bedane, Christoph ^e   Bernard, Philippe ^f   Caux, Frédéric ^g   Prost, Catherine ^g   Delaporte, Emmanuel ^h   Doutre, Marie Sylvie ⁱ   Dreno, Brigitte ^j   Franck, Nathalie ^k   Ingen Housz Oro, Saskia ^l   Chosidow, Olivier ^l   Pauwels, Christine ^m   Picard, Catherine ⁿ   Roujeau, Jean Claude ^l   Sigal, Michèle ^o   Tancrede Bohin, Emmanuell ^p   Templier, Isabelle ^q   Eming, Rüdiger ^r   Hertl, Michael ^r   D'Incan, Michel ^s   Joly, Pascal ^a   Musette, Philippe ^a   more..

^a NORMANDIE UNIVERSITÉ   (France)

^b UNIVERSITY OF ROUEN   (France)

^c INSERM   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f REIMS UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ PARIS 13   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ HAUT LÉVÊQUE HOSPITAL   (France)

^j NANTES UNIVERSITY HOSPITAL   (France)

^k université Paris Cité   (France)

^l HENRI MONDOR HOSPITAL   (France)

^m CENTRE HOSPITALIER INTERCOMMUNAL   (France)

ⁿ BICHAT HOSPITAL   (France)

^o CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^p SAINT LOUIS HOSPITAL   (France)

^q GRENOBLE UNIVERSITY HOSPITAL   (France)

^r PHILIPPS UNIVERSITY MARBURG   (Germany)

^s UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DESMOGLEIN; DESMOGLEIN ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 10; PREDNISONE; RITUXIMAB;

ARTICLE; B LYMPHOCYTE; CELL MATURATION; CELL SELECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNE DEFICIENCY; HUMORAL IMMUNITY; LYMPHOCYTE SUBPOPULATION; MEMORY CELL; PEMPHIGUS; PRE B LYMPHOCYTE; PRIORITY JOURNAL; REMISSION; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; DESMOGLEINS; HUMANS; IMMUNOPHENOTYPING; PEMPHIGUS;

EID: 84875172601     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3005166     Document Type: Article

References (42)

1. J. R. Stanley, Pemphigus and pemphigoid as paradigms of organ-specific, autoantibodymediated diseases. J. Clin. Invest. 83, 1443-1448 (1989). (Pubitemid 19124095)
2. M. Amagai, in Dermatology, J. L. Bolognia, J. L. Jorizzo, R. P. Rapini, Eds. (Mosby Elsevier, Toronto, 2008).
3. S. M. Langan, L. Smeeth, R. Hubbard, K. M. Fleming, C. J. Smith, J. West, Bullous pemphigoid and pemphigus vulgaris-Incidence and mortality in the UK: Population based cohort study. BMJ 337, a180 (2008).
4. R. W. Eyre, J. R. Stanley, Human autoantibodies against a desmosomal protein complex with a calcium-sensitive epitope are characteristic of pemphigus foliaceus patients. J. Exp. Med. 165, 1719-1724 (1987). (Pubitemid 17087919)
5. M. Amagai, V. Klaus-Kovtun, J. R. Stanley, Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 67, 869-877 (1991). (Pubitemid 121001501)
6. T. Hashimoto, M. Amagai, D. R. Garrod, T. Nishikawa, Immunofluorescence and immunoblot studies on the reactivity of pemphigus vulgaris and pemphigus foliaceus sera with desmoglein 3 and desmoglein 1. Epithelial Cell Biol. 4, 63-69 (1995). (Pubitemid 26101133)
7. M. Sekiguchi, Y. Futei, Y. Fujii, T. Iwasaki, T. Nishikawa, M. Amagai, Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins. J. Immunol. 167, 5439-5448 (2001). (Pubitemid 33009785)
8. M. Amagai, K. Tsunoda, D. Zillikens, T. Nagai, T. Nishikawa, The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J. Am. Acad. Dermatol. 40, 167-170 (1999). (Pubitemid 29072792)
9. M. G. Mahoney, Z. Wang, K. Rothenberger, P. J. Koch, M. Amagai, J. R. Stanley, Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J. Clin. Invest. 103, 461-468 (1999). (Pubitemid 29094045)
10. M. Meurer, Immunosuppressive therapy for autoimmune bullous diseases. Clin. Dermatol. 30, 78-83 (2012).
11. Y. Inoue, K. Watanabe, Adverse Effects of Steroids (Nova Science Publishers, New York, 2008).
12. K. G. Saag, R. Koehnke, J. R. Caldwell, R. Brasington, L. F. Burmeister, B. Zimmerman, J. A. Kohler, D. E. Furst, Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events. Am. J. Med. 96, 115-123 (1994). (Pubitemid 24070529)
13. L. Fardet, A. Flahault, A. Kettaneh, K. P. Tiev, T. Géné reau, C. Tolédano, C. Lebbé, J. Cabane, Corticosteroid-induced clinical adverse events: Frequency, risk factors and patient's opinion. Br. J. Dermatol. 157, 142-148 (2007). (Pubitemid 46934268)
14. Y. H. Lee, S. C. Bae, G. G. Song, The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials. Rheumatol. Int. 31, 1493-1499 (2011).
15. M. Ramos-Casals, C. Diaz-Lagares, M. J. Soto-Cardenas, P. Brito-Zeron, M. J. Cuadrado, G. Sanna, L. Bertolaccini, M. A. Khamashta, Rituximab therapy in lupus nephritis: Current clinical evidence. Clin. Rev. Allergy Immunol. 40, 159-169 (2011).
16. T. Dörner, D. Isenberg, D. Jayne, H. Wiendl, D. Zillikens, G. Burmester; International Roundtable on B cells as Therapeutic Target for Intervention, Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun. Rev. 9, 82-89 (2009).
17. M. Kasperkiewicz, E. Schmidt, D. Zillikens, Current therapy of the pemphigus group. Clin. Dermatol. 30, 84-94 (2012).
18. P. Joly, H. Mouquet, J. C. Roujeau, M. D'Incan, D. Gilbert, S. Jacquot, M. L. Gougeon, C. Bedane, R.Muller, B. Dreno, M. S. Doutre, E. Delaporte, C. Pauwels, N. Franck, F. Caux, C. Picard, E. Tancrede-Bohin, P. Bernard, F. Tron, M. Hertl, P. Musette, A single cycle of rituximab for the treatment of severe pemphigus. N. Engl. J. Med. 357, 545-552 (2007). (Pubitemid 47236279)
19. H. Mouquet, P. Musette, M. L. Gougeon, S. Jacquot, B. Lemercier, A. Lim, D. Gilbert, I. Dutot, J. C. Roujeau, M. D'Incan, C. Bedane, F. Tron, P. Joly, B-cell depletion immunotherapy in pemphigus: Effects on cellular and humoral immune responses. J. Invest. Dermatol. 128, 2859-2869 (2008).
20. A. R. Ahmed, Z. Spigelman, L. A. Cavacini, M. R. Posner, Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N. Engl. J. Med. 355, 1772-1779 (2006). (Pubitemid 44631360)
21. S. Matsukura, S. R. Knowles, S. Walsh, N. H. Shear, Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: A case series of 9 patients. Arch. Dermatol. 148, 734-739 (2012).
22. G. Cianchini, F. Lupi, C. Masini, R. Corona, P. Puddu, O. De Pità, Therapy with rituximab for autoimmune pemphigus: Results from a single-center observational study on 42 cases with long-term follow-up. J. Am. Acad. Dermatol. 67, 617-622 (2012).
23. E. E. Craythorne, G. Mufti, A. W. DuVivier, Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. J. Am. Acad. Dermatol. 65, 1064-1065 (2011).
24. J. D. Bouaziz, K. Yanaba, T. F. Tedder, Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev. 224, 201-214 (2008).
25. P. A. Blair, L. Y. Noreña, F. Flores-Borja, D. J. Rawlings, D. A. Isenberg, M. R. Ehrenstein, C. Mauri, CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32, 129-140 (2010).
26. J. Boye, T. Elter, A. Engert, An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann. Oncol. 14, 520-535 (2003). (Pubitemid 41295078)
27. J. H. Anolik, D. Campbell, R. E. Felgar, F. Young, I. Sanz, J. Rosenblatt, R. J. Looney, The relationship of FcgRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48, 455-459 (2003). (Pubitemid 36278014)
28. S. Roulland, F. Suarez, O. Hermine, B. Nadel, Pathophysiological aspects of memory B-cell development. Trends Immunol. 29, 25-33 (2008).
29. O. Thaunat, E. Morelon, T. Defrance, Am"B"valent: Anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis. Blood 116, 515-521 (2010).
30. J. H. Anolik, J. Barnard, T. Owen, B. Zheng, S. Kemshetti, R. J. Looney, I. Sanz, Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 56, 3044-3056 (2007). (Pubitemid 47502752)
31. M. J. Leandro, G. Cambridge, M. R. Ehrenstein, J. C. Edwards, Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54, 613-620 (2006). (Pubitemid 43228639)
32. T. Matsushita, K. Yanaba, J. D. Bouaziz, M. Fujimoto, T. F. Tedder, Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118, 3420-3430 (2008).
33. Y. Tamimoto, T. Horiuchi, H. Tsukamoto, J. Otsuka, H. Mitoma, Y. Kimoto, H. Nakashima, K. Muta, Y. Abe, C. Kiyohara, A. Ueda, K. Nagasawa, S. Yoshizawa, T. Shimoda, M. Harada, A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: Immunological analysis of B cells, T cells and cytokines. Rheumatology 47, 821-827 (2008). (Pubitemid 351796367)
34. P. P. Sfikakis, J. N. Boletis, S. Lionaki, V. Vigklis, K. G. Fragiadaki, A. Iniotaki, H. M. Moutsopoulos, Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial. Arthritis Rheum. 52, 501-513 (2005). (Pubitemid 40216314)
35. R. Eming, A. Nagel, S. Wolff-Franke, E. Podstawa, D. Debus, M. Hertl, Rituximab exerts a dual effect in pemphigus vulgaris. J. Invest. Dermatol. 128, 2850-2858 (2008).
36. M. J. Glennie, R. R. French, M. S. Cragg, R. P. Taylor, Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44, 3823-3837 (2007). (Pubitemid 47332625)
37. K. Owczarczyk, P. Lal, A. R. Abbas, K. Wolslegel, C. T. Holweg, W. Dummer, A. Kelman, P. Brunetta, N. Lewin-Koh, M. Sorani, D. Leong, P. Fielder, D. Yocum, C. Ho, W. Ortmann, M. J. Townsend, T. W. Behrens, A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci. Transl. Med. 3, 101ra92 (2011).
38. M. J. Guerry, P. Brogan, I. N. Bruce, D. P. D'Cruz, L. Harper, R. Luqmani, C. D. Pusey, A. D. Salama, D. G. Scott, C. O. Savage, R. A. Watts, D. R. Jayne, Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology 51, 634-643 (2012).
39. E. P. Rhee, K. A. Laliberte, J. L. Niles, Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin. J. Am. Soc. Nephrol. 5, 1394-1400 (2010).
40. R. B. Jones, A. J. Ferraro, A. N. Chaudhry, P. Brogan, A. D. Salama, K. G. Smith, C. O. Savage, D. R. Jayne, A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 60, 2156-2168 (2009).
41. D. F. Murrell, S. Dick, A. R. Ahmed, M. Amagai, M. A. Barnadas, L. Borradori, J. C. Bystryn, G. Cianchini, L. Diaz, D. Fivenson, R. Hall, K. E. Harman, T. Hashimoto, M. Hertl, N. Hunzelmann, P. Iranzo, P. Joly, M. F. Jonkman, Y. Kitajima, N. J. Korman, L. K. Martin, D. Mimouni, A. G. Pandya, A. S. Payne, D. Rubenstein, H. Shimizu, A. A. Sinha, D. Sirois, D. Zillikens, V. P. Werth, Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J. Am. Acad. Dermatol. 58, 1043-1046 (2008).
42. A. Lim, B. Lemercier, X. Wertz, S. L. Pottier, F. Huetz, P. Kourilsky, Many human peripheral VH5-expressing IgM+ B cells display a unique heavy-chain rearrangement. Int. Immunol. 20, 105-116 (2008).